Nomifensine (Merital Alival) is a norepinephrine-dopamine reuptake inhibitor developed by a team at Hoechst AG in the 1960s. The drug was test marketed in the United States by Hoechst AG (now Sanofi-Aventis) i.e. a drug that increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters.
This page contains content from the copyrighted Wikipedia article "Nomifensine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
